Although significant progress has been made in the development of therapeutic strategies for COVID-19, including anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, nucleoside analogues, protease inhibitors, and monoclonal antibodies, clinical management of severe cases remains challenging. Here, ACE is linked to COVID-19.